Moxifloxacin Ophthalmic
Phase 3
Moxifloxacin Ophthalmic is one of 4 therapeutic programs targeting Bacterial Keratitis. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in Bacterial Keratitis
#DrugCompanyPhaseTrials
1Avelox
BayerPhase 3
Durezol
NovartisPhase 3
Moxifloxacin Ophthalmic
UUniversity of California, San Francisco
Phase 3
Rose Bengal
UUniversity of California, San Francisco
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Moxifloxacin Ophthalmic. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]